skip to content


The Mirror report discovery that could help tailor vaccinations for people in future

31 July 2023

The Mirror covered the latest exciting research from the Thaventhiran lab in collaboration with researchers across the University of Cambridge. Described as a "huge step forward" by Dr Miriam Stoppard, the discovery made by Unit researchers may explain why, even among vulnerable patient groups, some have better responses...

Read more

‘Ageing’ immune cell levels could predict how well we respond to vaccines

27 June 2023

Researchers from the MRC Toxicology Unit have identified a signature in the blood that could help predict how well an individual will respond to vaccines. The discovery, published today in the journal Nature Communications, may explain why, even among vulnerable patient groups, some individuals have better responses to...

Read more

National papers and local radio cover obesity and vaccine response research

16 May 2023

Work published by Dr James Thaventhiran and collaborators in Cambridge and Edinburgh describing how obesity accelerates the loss of protection from COVID-19 vaccines was reported across national media outlets. Dr Thaventhiran was also interviewed about their findings on local radio. You can read the Unit's news article and...

Read more

People with obesity lose immunity gained from COVID-19 vaccination more rapidly

11 May 2023

The protection offered by COVID-19 vaccination declines more rapidly in people with severe obesity compared to those with normal weight, researchers from the MRC Toxicology Unit and collaborators within the Universities of Cambridge and Edinburgh have found. The study suggests that people with obesity are likely to need...

Read more

Obesity and COVID-19: when two pandemics collide

24 September 2022

Elderberries, flaxseeds, manuka honey, garlic and the juice of an orange. A recipe for a vampire-repelling poultice, perhaps? No, but these ingredients have all made their way from ancient folklore into current public consciousness as “immune-boosting superfoods”. The midst of a global infectious disease pandemic is a...

Read more

Nature Communications featured article: Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

1 March 2021

A recently publised article from Dr. James Thaventhiran's group about the potential treatment effect of remedesvir in COVID-19 patients was chosen as a featured paper by Nature Communiactions. The scientific achivement is highlighted under the topic of "Microbiology and Infectious diseases" in the journal's January issue .

Read more

Remdesivir likely to be highly effective antiviral against SARS-CoV-2

14 December 2020

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists. Writing in Nature Communications, the researchers describe giving the drug to a patient with COVID-19 and a rare immune disorder, and observing a dramatic improvement in his symptoms and...

Read more

Researchers test a drug that may allow more cancer patients to benefit from immunotherapy in the future

3 November 2020

Immunotherapy can be a lifesaver for cancer patients, but some patients' tumours don't respond well to this treatment. However, researchers are encouraged by a recent clinical trial that suggests that it may be possible to expand immunotherapy to help more people in the future. Immunotherapy works by marshalling the body's...

Read more

Dr James Thaventhiran joins Dr Nicholas Matheson for the CITIID's weekly COVID-19 update

21 April 2020

On the 16th April, Dr James Thaventhiran joined Dr Nicholas Matheson for the Cambridge Institute of Therapeutic Immunology and Infectious Disease's (CITIID) weekly COVID-19 update. This talk, along with all other previous updates from the CITIID, can be found here. Details of the weekly webinar can be found here . Each...

Read more

Thaventhiran lab's publication selected as one of the top ten papers of 2019 by the Journal of Experimental Medicine

19 March 2020

The Thaventhiran lab's paper 'Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses' has been selected as one of the Top Ten Papers of 2019 by the Journal of Experimental Medicine (JEM). Brief Definitive Report Interleukin-6 receptor deficiency Sarah Spencer; Sevgi Köstel...

Read more